http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2842500-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3a9df6734836f928dbfa95a3bb31459c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-216 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5078 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5084 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5047 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-216 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 |
| filingDate | 2012-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b1a385190833cea9a7435066734bcee http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4cd8ab0a280ca78689b1091e5c5f3771 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3cdb0573819b18ccf10881262af5cefa |
| publicationDate | 2021-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2842500-T3 |
| titleOfInvention | Fenofibrate formulation |
| abstract | A dosage form comprising a plurality of beads or particles, each of said beads or particles comprising: a drug selected from the group consisting of fenofibric acid, pharmaceutically acceptable salts thereof, pharmaceutically acceptable esters thereof, and prodrugs thereof; from 0.3% to 10% by weight of said beads or particles of a surfactant; and from 5% to 15% by weight of said beads or particles of a water-soluble or water-dispersible cellulosic binder; wherein the mass ratio of said drug to said binder in said dosage form 3.5: 1 and 4.5: 1; and wherein said dosage form produces a first Cmax in vivo that is between 10% and 50% higher than a comparative Cmax produced by a comparative dosage form comprising said drug and said binder in a ratio of between 5: 1 and 15: 1 and from 1% to 10% by weight of said surfactant; said dosage form and said comparative dosage form have the same amount of drug. |
| priorityDate | 2012-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 99.